Non-Small Cell Lung Cancer iNewsletter Series
Approximately 87% of lung cancer cases in the U.S. are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage with poor overall survival. Major steps in the molecular era of lung cancer treatment are being made as clinicians not only rely on histologic classification of lung cancer to guide therapy, but also define lung cancer tumor types based on specific molecular profiles. The use of molecularly targeted therapies represents a significant advance in the treatment of NSCLC.
The gap between optimal management of advanced NSCLC and current clinical practice is widening as many oncologists remain unaware of how best to apply new and emerging clinical evidence into their clinical practice. Oncologists and other cancer professionals have an opportunity to prolong life and improve the quality of life in selected patients with advanced NSCLC by more thoroughly defining molecular subsets of advanced NSCLC and more fully integrating the use of targeted therapies into treatment regimens.
This fourth and final i-newsletter issue in this series focuses on promising emerging oncogenes and targeted therapies.
This third i-Newsletter issue focuses on the evolving use of bevacizumab.
This second i-Newsletter issue focuses on defining and treating NSCLC patients with EGFR-TKI acquired resistance.
This newsletter issue focuses on steps to identify and treat NSCLC who test positive for ALK rearrangement.